Literature DB >> 33103184

Impact of a multidisciplinary workflow on safety and management of patients with heparin-induced thrombocytopenia.

Kalynn A Northam1, Sheh-Li Chen1, Andrew P Stivers2, Jonathan D Cicci1, Tanner L Hedrick1, Marian A Rollins-Raval3, Raj S Kasthuri4.   

Abstract

PURPOSE: Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin administration. Management strategies are complex and include discontinuing heparin products, initiating alternative anticoagulants, interpreting laboratory test results, documenting heparin allergies, and providing patient education. Medication error reports and a retrospective review conducted at an academic medical center revealed an opportunity for a quality improvement initiative and led to the creation of a multidisciplinary workflow for the management of HIT. In a pre-post study, the impact of the multidisciplinary workflow on the safety and management of HIT was evaluated.
METHODS: The preimplementation group consisted of adult patients tested for suspected HIT from April 4, 2014, through May 31, 2016; the postimplementation group consisted of adult patients tested from November 1, 2016, through October 31, 2018. The primary outcome was the incidence of heparin product administration while HIT testing was ongoing. The secondary outcome was the rate of appropriate heparin allergy documentation.
RESULTS: The incidence of heparin product administration while HIT testing results were pending was significantly reduced, from 54.2% to 20.0% (P < 0.001), after workflow implementation. The rate of appropriate heparin allergy documentation significantly increased, from 95.0% to 100% (P < 0.001).
CONCLUSION: Implementation of a multidisciplinary workflow for the management of HIT significantly reduced the incidence of heparin administration while testing was ongoing and improved the rate of appropriate heparin allergy documentation. © American Society of Health-System Pharmacists 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  anticoagulants; documentation; heparin; quality improvement; thrombocytopenia

Mesh:

Substances:

Year:  2021        PMID: 33103184      PMCID: PMC7947986          DOI: 10.1093/ajhp/zxaa342

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  10 in total

1.  The effect of residual heparin on the interpretation of heparin-induced platelet aggregation in the diagnosis of heparin-associated thrombocytopenia.

Authors:  M M White; L Siders; L K Jennings; F L White
Journal:  Thromb Haemost       Date:  1992-07-06       Impact factor: 5.249

Review 2.  Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient).

Authors:  Lawrence Rice
Journal:  Arch Intern Med       Date:  2004-10-11

3.  Prospective evaluation of the interobserver reliability of the 4Ts score in patients with suspected heparin-induced thrombocytopenia.

Authors:  M Nagler; T Fabbro; Walter A Wuillemin
Journal:  J Thromb Haemost       Date:  2012-01       Impact factor: 5.824

Review 4.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  ASHP Guidelines on Preventing Medication Errors in Hospitals.

Authors:  Molly Billstein-Leber; Col Jorge D Carrillo; Angela T Cassano; Kym Moline; Jennifer J Robertson
Journal:  Am J Health Syst Pharm       Date:  2018-10-01       Impact factor: 2.637

6.  Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study.

Authors:  Lori-Ann Linkins; Shannon M Bates; Agnes Y Y Lee; Nancy M Heddle; Grace Wang; Theodore E Warkentin
Journal:  Blood       Date:  2015-04-29       Impact factor: 22.113

7.  Inappropriate documentation of heparin allergy in the medical record because of misdiagnosis of heparin-induced thrombocytopenia: frequency and consequences.

Authors:  C M McMahon; Y C Tanhehco; A Cuker
Journal:  J Thromb Haemost       Date:  2016-12-24       Impact factor: 5.824

8.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Gowthami M Arepally; Beng H Chong; Douglas B Cines; Andreas Greinacher; Yves Gruel; Lori A Linkins; Stephen B Rodner; Sixten Selleng; Theodore E Warkentin; Ashleigh Wex; Reem A Mustafa; Rebecca L Morgan; Nancy Santesso
Journal:  Blood Adv       Date:  2018-11-27

9.  Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program.

Authors:  Brianne M Ritchie; Katelyn W Sylvester; David P Reardon; William W Churchill; Nancy Berliner; Jean M Connors
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

10.  Heparin-induced thrombocytopenia: reducing misdiagnosis via collaboration between an inpatient anticoagulation pharmacy service and hospital reference laboratory.

Authors:  Allison E Burnett; Harmony Bowles; Matthew E Borrego; Tiffany N Montoya; David A Garcia; Charles Mahan
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.